Cellectis S.A. (NASDAQ:CLLS) and bluebird bio Inc. (NASDAQ:BLUE) compete against each other in the Biotechnology sector. We will contrast them and contrast their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis S.A.	25.47M	28.27	82.53M	-2.11	0.00
bluebird bio Inc.	39.50M	185.53	523.83M	-8.19	0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Cellectis S.A. and bluebird bio Inc.

Profitability

Table 2 shows Cellectis S.A. and bluebird bio Inc.’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Cellectis S.A.	-324.03%	-23%	-18.8%
bluebird bio Inc.	-1,326.15%	-31.5%	-26.6%

Risk and Volatility

Cellectis S.A. has a 1.7 beta, while its volatility is 70.00% which is more volatile than Standard & Poor’s 500. In other hand, bluebird bio Inc. has beta of 2.44 which is 144.00% more volatile than Standard & Poor’s 500.

Liquidity

11.2 and 11.2 are the respective Current Ratio and a Quick Ratio of Cellectis S.A. Its rival bluebird bio Inc.’s Current and Quick Ratios are 13.1 and 13.1 respectively. bluebird bio Inc. has a better chance of clearing its pay short and long-term debts than Cellectis S.A.

Analyst Recommendations

Ratings and Recommendations for Cellectis S.A. and bluebird bio Inc. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cellectis S.A.	0	1	0	2.00
bluebird bio Inc.	0	2	5	2.71

Cellectis S.A.’s upside potential is 47.67% at a $25 average price target. On the other hand, bluebird bio Inc.’s potential upside is 10.32% and its average price target is $147.83. Based on the results delivered earlier, Cellectis S.A. is looking more favorable than bluebird bio Inc., analysts opinion.

Institutional & Insider Ownership

Cellectis S.A. and bluebird bio Inc. has shares owned by institutional investors as follows: 29.4% and 0%. Comparatively, bluebird bio Inc. has 0.3% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cellectis S.A.	-12.03%	-27.86%	-25.47%	-35.88%	-21.71%	-33.55%
bluebird bio Inc.	-16.88%	-23.58%	-30.98%	-43.22%	-39.16%	-42.64%

For the past year Cellectis S.A. has stronger performance than bluebird bio Inc.

Summary

On 8 of the 12 factors Cellectis S.A. beats bluebird bio Inc.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.